Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors. It is characterized by muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids (e.g., prednisone), and short- and long-term immunosuppressants (e.g., mycophenolate mofetil, azathioprine) are the most prescribed agents to manage the symptoms of MG. Since the launch of eculizumab (Alexion / AstraZeneca’s Soliris) in 2017, a new wave of MG therapies with unique mechanisms of action is starting to affect the treatment landscape in the United States, highlighted by the FDA’s approval of efgartigimod (Argenx’s Vyvgart) in 2021 and its subcutaneous version in 2023, ravulizumab (Alexion / AstraZeneca’s Ultomiris) in 2022, and rozanolixizumab (UCB’s Rystiggo) in 2023. As the treatment landscape for MG continues to evolve, this report offers insight based on real-world claims data into prescribing trends for MG to help new players understand current treatment practices and define the market niche for their emerging products.
Questions answered
Content highlights
Markets covered: United States
Key drugs: Soliris, Vyvgart, Ultomiris, Rystiggo, pyridostigmine
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.